Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic
Sven Saussez,
Luigi Angelo Vaira,
Giacomo De Riu,
Jérome R. Lechien
Affiliations
Sven Saussez
Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium
Luigi Angelo Vaira
Maxillofacial Surgery Operative Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
Giacomo De Riu
Maxillofacial Surgery Operative Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
Jérome R. Lechien
Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium
At the beginning of 2021, the scientific community realized the burden of COVID-19-related persistent olfactory disorders (ODs). The percentage of those infected with COVID-19 who developed severe and persistent ODs [1–3] with devastating effects on their quality of life was 5 to 40% [4,5].
